2XMY

Discovery and Characterisation of 2-Anilino-4-(thiazol-5-yl) pyrimidine Transcriptional CDK Inhibitors as Anticancer Agents

Structural Biology Knowledgebase: 2XMY SBKB.org


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.9 Å
  • R-Value Free: 0.271
  • R-Value Work: 0.189

wwPDB Validation Full Report


Literature

Macromolecules
Sequence Display for 2XMY

Classification: TRANSFERASE

Total Structure Weight: 34412.32

Macromolecule Entities
Molecule Chains Length Organism Details
CELL DIVISION PROTEIN KINASE 2 A 298 Homo sapiens EC#: 2.7.11.22 IUBMB
Gene Name(s): CDK2 Gene View CDKN2

Small Molecules
Ligands 1 Unique
ID Chains Name / Formula / InChI Key 2D Diagram 3D Interactions
CDK
Query on CDK

A 4-[4-(3,4-DIMETHYL-2-OXO-2,3-DIHYDRO-THIAZOL- 5-YL)-PYRIMIDIN-2-YLAMINO]-N-(2-METHOXY-ETHYL)- BENZENESULFONAMIDE
C18 H21 N5 O4 S2
WQZVTNFUNLTGDW-UHFFFAOYSA-N
Ligand Explorer
 
Binding Pocket (JSmol)
 
Electron Density (JSmol)
External Ligand Annotations
ID Binding Affinity (Sequence Identity %)
CDK Ki: 0.11 nM (100) BindingDB

Ki: 0.11 nM  BindingMOAD
Ki: 0.11 nM  PDBbind

Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.9 Å
  • R-Value Free: 0.271
  • R-Value Work: 0.189
  • Space Group: P 21 21 21
  • Electron Density Server: EDS EDS

Unit Cell:

Length (Å) Angle (°)
a = 53.12 α = 90.00
b = 71.50 β = 90.00
c = 71.64 γ = 90.00

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History

Deposition Data

  • Deposited Date: 2010-07-29
  • Released Date: 2010-11-10
  • Deposition author(s): Wang, S., Griffiths, G., Midgley, C.A., Barnett, A.L., Cooper, M., Grabarek, J., Ingram, L., Jackson, W., Kontopidis, G., Mcclue, S.J., Mcinnes, C., Mclachlan, J., Meades, C., Mezna, M., Stuart, I., Thomas, M.P., Zheleva, D.I., Lane, D.P., Jackson, R.C., Glover, D.M., Blake, D.G., Fischer, P.M.

Revision History

  • 2012-03-28
    Type: Source and taxonomy | Details: SOURCE
  • 2012-03-28
    Type: Other | Details: REMARK 900
  • 2012-03-28
    Type: Refinement description | Details: REMARK 3
  • 2012-03-28
    Type: Citation | Details: JRNL
  • 2012-03-28
    Type: Version format compliance | Details: REMARK 4